All News

In the intervention group, the HRQOL score changed by 23.9 points between baseline and week 13, from 18.4 to 29.5.

Overall, participating pathologists felt that there is potential to increase diagnostic efficiency by using Ibex Prostate in a clinical setting.

Treatment with SBRT showed a minimal effect on prostate cancer-specific HRQL measures in regard to urinary incontinence domain scores, urinary irritative/obstructive domain scores, and bowel domain scores.

Tepidimonas was notably associated with more severe urinary incontinence episodes, suggesting a potential marker for identifying individuals at risk for more severe symptoms.

With the dosing of the first patient in Italy, Telix’s expanded access program for TLX250-CDx in ccRCC now includes 3 active countries, including the Netherlands and the US.

ADV7103 is currently being studied in the phase 2/3 CORAL-1 study, enrolling patients with cystinuria across centers in France and Belgium.

Developed by the AUGS Scientific Committee and Research Agenda Writing Group

"The implications for urology, and every specialty, are immense. It does improve care, and it helps the patient. I think this is what it will be, it just may take some time," says Vipul Patel, MD.

"Indeed, HSD3B1 appears to be the most common monogenic driver of prostate cancer mortality,” says Nima Sharifi, MD.

"Per CPT coding instructions, when procedures or services performed by physicians do not have a valid or descriptive CPT or Healthcare Common Procedure Coding System (HCPCS) code, the service should be reported using an unlisted code," write Jonathan Rubenstein, MD, and Mark Painter.

In this episode of Speaking of Urology®, Eugene Rhee, MD, MBA, and Logan Galansky, MD, discuss key topics in health policy and recap the AUA's recent Annual Urology Advocacy Summit.

"We suspect that 340B hospitals potentially have some resources or mechanisms that are helping these vulnerable patients maintain adherence,” says Kassem S. Faraj, MD.

“What is becoming increasingly evident is that the traditional health care model is falling short for patients in rural regions,” says Ramy Abou Ghayda, MD, MPH, MBA candidate.

"The ProVee System has the potential to be a first-line interventional therapy for BPH that can be safely and reliably performed in the office setting," says Steven A. Kaplan, MD.

The EdgeFlow UH10 bladder scanner utilizes high-resolution ultrasound imaging to non-invasively measure postvoid residual urine in the bladder.

According to Axonics, commercial sales of the R20 system in Europe are expected to begin in mid-April.

Overall, the phase 1/2 trial is designed to explore the safety, tolerability, pharmacokinetics, and preliminary clinical activity of NUV-1511 in patients with advanced solid tumors.

"I am still struggling with disposing the scopes after each use, both from the environmental aspect and the fact that the scope technically can be used more than once," writes Gopal H. Badlani, MD.

"The combination of highly potent systemic therapy and targeted radiation has shown impressive results in maintaining low PSA levels after testosterone recovery, offering hope for improved outcomes in these patients, but further studies are still needed to determine the best regimen," says Amar U. Kishan, MD.

Among all patients treated in the study to date, 60% demonstrated a PSA reduction of greater than 35%, and 27% demonstrated a PSA reduction of greater than 80%.

The therapy, known as Autologous Muscle Derived Cells for Urinary Sphincter Repair (iltamiocel), involves a medical procedure in which a participant’s own muscle cells are collected, processed, and then injected into the tissues of the urinary passage.

The VISTA-101 study has dosed all patients at dose level 5 of 6 in the KVA12123 monotherapy arm and all patients at the dose level 2 of 4 in the KVA12123-pembrolizumab combination arm.

The application for UGN-102 for low-grade intermediate-risk non–muscle-invasive bladder cancer is based on findings from the phase 3 ENVISION trial.

The odds of SUI recurrence following MUS were 17% to 24% among patients with childbirth vs 15% to 22% among patients without childbirth

The study is assessing RECCE 327 across the infusion times of 15, 20, 30, 45, and 60 minutes at the dose level of 3000 mg.

“Remarkably, relugolix demonstrated a faster return to baseline testosterone levels compared [with] traditional therapies, a crucial aspect for patients' quality of life post-treatment," says Daniel E. Spratt, MD.

Interest in AI in prostate cancer pathology has picked up speed since initial attempts of computer-aided diagnosis of the disease more than a decade ago, according to Peter A. Humphrey, MD, PhD.

"[Telemedicine] really has demonstrated itself to be a tool that can be used in a variety of ways, according to the discretion and ingenuity of the urologist," says Aaron Spitz, MD.